SEC Form 4 · accession 0001209191-15-023560
CONCERT PHARMACEUTICALS, INC. · CNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James V Cassella
Officer — Chief Development Officer
Period of report
Mar 5, 2015
Accepted (ET)
Mar 6, 2015 · 4:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367920
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $14.46 | Mar 5, 2015 | A | 140,000 | A | — | Mar 4, 2025 | Common Stock | 140,000 | 140,000 | D |
Explanation of responses
- F1This option vests as to 25% of the original 140,000 shares on February 2, 2016 and vests as to an additional 6.25% of the original shares at the end of each successive three-month period through and including February 2, 2019.